The importance of brain banks for molecular neuropathological research: The new south wales tissue resource centre experience

International Journal of Molecular Sciences

Volumn 10, Issue 1, 2009, Pages 366-384

  Dedova, Irina ^a,b   Harding, Antony ^b   Sheedy, Donna ^b   Garrick, Therese ^b   Sundqvist, Nina ^a,b   Hunt, Clare ^b   Gillies, Juliette ^a,b   Harper, Clive G ^b  

^a SCHIZOPHRENIA RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Alcohol; Brain bank; Clinical characterization; Genome; Human; Molecular neuropathology; Postmortem; Proteome; Receptor binding; Schizophrenia

Indexed keywords

ALCOHOLISM; AUSTRALIA; BRAIN; BRAIN TISSUE; DIFFUSE LEWY BODY DISEASE; FRONTOTEMPORAL DEMENTIA; HUMAN; MEDICAL INFORMATION; MEDICAL RESEARCH; MOLECULAR BIOLOGY; NEUROPATHOLOGY; NEUROSCIENCE; ORGAN PRESERVATION; PARKINSON DISEASE; PATHOPHYSIOLOGY; QUALITY CONTROL; REVIEW; SCHIZOPHRENIA;

ALCOHOL; BRAIN BANK; CLINICAL CHARACTERIZATION; GENOME; HUMAN; MOLECULAR NEUROPATHOLOGY; POSTMORTEM; PROTEOME; RECEPTOR BINDING; SCHIZOPHRENIA;

BIOLOGICAL SPECIMEN BANKS; BRAIN; HUMANS; NEUROLOGY; PATHOLOGY, CLINICAL; WALES;

EID: 59649119219     PISSN: None     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms10010366     Document Type: Review

References (90)

1. Boguski, M.; Jones, A. Neurogenomics: At the intersection of neurobiology and genome sciences. Nat. Neurosci. 2004, 7, 429-433.
2. World Health Organization. Disease incidence, prevalence and disability. In World Health Organisation- Global Burden of Disease - 2004 update 2008; pp. 28-37.
3. Bell, J.E.; Alafuzoff, I.; Al-Sarraj, S.; Arzberger, T.; Bogdanovic, N.; Budka, H.; Dexter, D.T.; Falkai, P.; Ferrer, I.; Gelpi, E.; Gentleman, S.M.; Giaccone, G.; Huitinga, I.; Ironside, J.W.; Klioueva, N.; Kovacs, G.G.; Meyronet, D.; Palkovits, M.; Parchi, P.; Patsouris, E.; Reynolds, R.; Riederer, P.; Roggendorf, W.; Seilhean, D.; Schmitt, A.; Schmitz, P.; Streichenberger, N.; Schwalber, A.; Kretzschmar, H. Management of a twenty-first century brain bank: experience in the BrainNet Europe consortium. Acta Neuropathol. 2008, 115, 497-507.
4. Schmitt, A.; Bauer, M.; Heinsen, H.; Feiden, W.; Falkai, P.; Alafuzoff, I.; Arzberger, T.; Al-Sarraj, S.; Bell, J.E.; Bogdanovic, N.; Bruck, W.; Budka, H.; Ferrer, I.; Giaccone, G.; Kovacs, G.G.; Meyronet, D.; Palkovits, M.; Parchi, P.; Patsouris, E.; Ravid, R.; Reynolds, R.; Riederer, P.; Roggendorf, W.; Schwalber, A.; Seilhean, D.; Kretzschmar, H. How a neuropsychiatric brain bank should be run: A consensus paper of Brainnet Europe II. J. Neural. Transm. 2007, 114, 527-537.
5. Schmitt, A.; Parlapani, E.; Bauer, M.; Heinsen, H.; Falkai, P. Is brain banking of psychiatric cases valuable for neurobiological research? Clinics 2008, 63, 255-266.
6. Kretzschmar, H. Brain banking: Opportunities, challenges and meaning for the future. Nat. Rev. Neurosci. 2009, 10, 70-78.
7. Sheedy, D.; Garrick, T.; Dedova, I.; Hunt, C.; Miller, R.; Sundqvist, N.; Harper, C. An Australian Brain Bank: A critical investment with a high return. Cell Tissue Bank 2008, 9, 205-216.
8. Chevyreva, I.; Faull, R.L.; Green, C.R.; Nicholson, L.F. Assessing RNA quality in postmortem human brain tissue. Exp. Mol. Pathol. 2008, 84, 71-77.
9. Lipska, B.K.; Deep-Soboslay, A.; Weickert, C.S.; Hyde, T.M.; Martin, C.E.; Herman, M.M.; Kleinman, J.E. Critical factors in gene expression in postmortem human brain: Focus on studies in schizophrenia. Biol. Psychiatry. 2006, 60, 650-658.
10. Stan, A.D.; Ghose, S.; Gao, X.M.; Roberts, R.C.; Lewis-Amezcua, K.; Hatanpaa, K.J.; Tamminga, C.A. Human postmortem tissue: what quality markers matter? Brain. Res. 2006, 1123, 1-11.
11. Tomita, H.; Vawter, M.P.; Walsh, D.M.; Evans, S.J.; Choudary, P.V.; Li, J.; Overman, K.M.; Atz, M.E.; Myers, R.M.; Jones, E.G.; Watson, S.J.; Akil, H.; Bunney, W.E., Jr. Effect of agonal and postmortem factors on gene expression profile: quality control in microarray analyses of postmortem human brain. Biol. Psychiatry. 2004, 55, 346-352.
12. Webster, M.J. Tissue preparation and banking. Prog. Brain. Res. 2006, 158, 3-14.
13. Harrison, P.J.; Heath, P.R.; Eastwood, S.L.; Burnet, P.W.; McDonald, B.; Pearson, R.C. The relative importance of premortem acidosis and postmortem interval for human brain gene expression studies: selective mRNA vulnerability and comparison with their encoded proteins. Neurosci. Lett. 1995, 200, 151-154.
14. Harper, C.; Garrick, T.; Matsumoto, I.; Pfefferbaum, A.; Adalsteinsson, E.; Sullivan, E.; Dodd, P.; Lewohl, J.; Butterworth, R. How important are brain banks for alcohol research? Alcohol. Clin. Exp. Res. 2003, 27, 310-323.
15. Hill, C.; Roberts, S.; Keks, N.; Dean, B.; Mackinnon, A.; Copolov, D. Diagnostic Instrument for Brain Studies- Revised; Mental Health Research Institute: Victoria, Australia, 2005.
16. th Ed.; American Psychiatric Association: Washington, DC, USA, 1994.
17. Garrick, T.; Glaw, X.; Harper, C.G.; North, A. The diagnosis is critical for psychiatric brain banks: An interrater reliability study. Aust. N. Z. J. Psychiatry. 2006, 40, 606-607.
18. Sundqvist, N.; Garrick, T.; Bishop, I.; Harper, C. Reliability of post-mortem psychiatric diagnosis for neuroscience research. Aust. N. Z. J. Psychiatry. 2008, 42, 221-227.
19. Flatscher-Bader, T.; Matsumoto, I.; Wilce, P. Smoking and alcoholism target genes associated with plasticity and glutamate transmission in the human VTA. Hum. Mol. Genet. 2008, 17, 38-51.
20. Flatscher-Bader, T.; Wilce, P.A. Chronic smoking and alcoholism change expression of selective genes in the human prefrontal cortex. Alcohol. Clin. Exp. Res. 2006, 30, 908-915.
21. Grinberg, L.T.; Ferretti, R.E.; Farfel, J.M.; Leite, R.; Pasqualucci, C.A.; Rosemberg, S.; Nitrini, R.; Saldiva, P.H.; Filho, W.J. Brain bank of the Brazilian aging brain study group - a milestone reached and more than 1,600 collected brains. Cell Tissue Bank 2007, 8, 151-162.
22. Vonsattel, J.P.; Del Amaya, M.P.; Keller, C.E. Twenty-first century brain banking. Processing brains for research: The Columbia University methods. Acta Neuropathol. 2008, 115, 509-532.
23. Waldvogel, H.J.; Bullock, J.Y.; Synek, B.J.; Curtis, M.A.; van Roon-Mom, W.M.; Faull, R.L. The collection and processing of human brain tissue for research. Cell Tissue Bank 2008, 9, 169-179.
24. Clark, D.D.I.; Cordwell, S.; Matsumoto, I. A proteome analysis of the anterior cingulate cortex gray matter in schizophrenia. Mol. Psychiatry. 2006, 11, 459-470.
25. Clark, D.; Dedova, I.; Cordwell, S.; Matsumoto, I., Altered proteins of the anterior cingulate cortex white matter proteome in schizophrenia. Proteomics. Clin. Appl. 2007, 1, 157-166.
26. Sivagnanasundaram, S.; Crossett, B.; Dedova, I.; Cordwell, S.; Matsumoto, I. Abnormal pathways on the genu of the corpus callosum in schizophrenia pathogenesis: a proteome study. Proteomics. Clin. Appl. 2007, 1, 1291-1305.
27. Alexander- Kaufman, K.; Dedova, I.; Harper, C.; Matsumoto, I. Proteome analysis of the dorsolateral prefrontal region from healthy individuals. Neurochem. Int. 2007, 5, 433-439.
28. Zavitsanou, K. M1 receptor agonism, a possible treatment for cognitive deficits in schizophrenia. Neuropsychopharmacology 2004, 29, 1585-1586.
29. Zavitsanou, K.; Garrick, T.; Huang, X.-F. Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2004, 28, 355-360.
30. Zavitsanou, K.; Katsifis, A.; Mattner, F.; Huang, X.-F. Investigation of m1/m4 muscarinic receptors in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression disorder. Neuropsychopharmacology 2004, 29, 619-625.
31. Zavitsanou, K.; Katsifis, A.; Yu, Y.; Huang, X.-F. M2/M4 muscarinic receptor binding in the anterior cingulate cortex in schizophrenia and mood disorders. Brain. Res. Bull. 2005, 65, 397-403.
32. Zavitsanou, K.; Ward, P.B.; Huang, X.-F. Selective alterations in ionotropic glutamate receptors in the anterior cingulate cortex in schizophrenia. Neuropsychopharmacology 2002, 27, 826-833.
33. 3H] spiperone binding in the anterior cingulate cortex of schizophrenia patients: An autoradiographic study. Neuroscience 2002, 109, 709-716.
34. Ito, M.; Depaz, I.; Wilce, P.; Suzuki, T.; Niwa, S.; Matsumoto, I. Expression of human neuronal protein 22, a novel cytoskeleton-associated protein, was decreased in the anterior cingulate cortex of schizophrenia. Neurosci. Lett. 2005, 378, 125-130.
35. Wheeler, D.G.; Harper, C.G. Localised reductions in gyrification in the posterior cingulate: Schizophrenia and controls. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2007, 31, 319-327.
36. Newell, K.A., Deng, C., and Huang, X.F. Increased cannabinoid receptor density in the posterior cingulate cortex in schizophrenia. Exp. Brain. Res. 2006, 172, 556-560.
37. Newell, K.A., Zavitsanou, K., Kum-Jew, S., and Huang, X.-F. Alterations of muscarinic and GABA receptor binding in the posterior cingulate cortex in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2007, 31, 225-233.
38. Newell, K.A.; Zavitsanou, K.; Huang, X.-F. Ionotropic glutamate receptor binding in the posterior cingulate cortex in schizophrenia patients. Neuroreport 2005, 16, 1363-1367.
39. Tooney, P.A.; Au, G.G.; Chahl, L.A. Tachykinin NK1 and NK3 receptors in the prefrontal cortex of the human brain. Clin. Exp. Pharmacol. Physiol. 2000, 27, 947-949.
40. Tooney, P.A.; Au, G.G.; Chahl, L.A., Localisation of tachykinin NK1 and NK3 receptors in the human prefrontal and visual cortex. Neurosci. Lett. 2000, 283, 185-188.
41. Tooney, P.A.; Crawter, V.C.; Chahl, L.A., Increased tachykinin NK(1) receptor immunoreactivity in the prefrontal cortex in schizophrenia. Biol. Psychiatry. 2001, 49, 523-527.
42. Ide, M.; Ohnishi, T.; Murayama, M.; Matsumoto, I.; Yamada, K.; Iwayama, Y.; Dedova, I.; Toyota, T.; Asada, T.; Takashima, A.; Yoshikawa, T. Failure to support a genetic contribution of AKT1 polymorphisms and altered AKT signaling in schizophrenia. J. Neurochem. 2006, 99, 277-287.
43. Tooney, P.A.; Chahl, L. A. Neurons expressing calcium-binding proteins in the prefrontal cortex in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2004, 28, 273-278.
44. Wheeler, D.G.; Dixon, G.; Harper, C.G. No differences in calcium-binding protein immunoreactivity in the posterior cingulate and visual cortex: schizophrenia and controls. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2006, 30, 630-639.
45. Deng, C.; Huang, X.-F. Decreased density of muscarinic receptors in the superior temporal gyrusin schizophrenia. J. Neurosci. Res. 2005, 81, 883-890.
46. Deng, C.; Huang, X.-F. Increased density of GABAA receptors in the superior temporal gyrus in schizophrenia. Exp. Brain. Res. 2006, 168, 587-590.
47. Bowden, N.; Scott, R.; Tooney, P. Altered gene expression in the superior temporal gyrus in schizophrenia. BMC Genomics 2008, 9, 199.
48. Bowden, N.A.; Scott, R.J.; Tooney, P.A. Altered expression of regulator of G-protein signalling 4 (RGS4) mRNA in the superior temporal gyrus in schizophrenia. Schizophr. Res. 2007, 89, 165- 168.
49. Beveridge, N.; Tooney, P.; Carroll, A.; Gardiner, E., Bowden, N.; Scott, R.; Tran, N.; Dedova, I.; Cairns, M. Dysregulation of miRNA 181b in the temporal cortex in schizophrenia. Hum. Mol. Genet. 2008, 17, 1156-1168.
50. Kapoor, R.; Lim, K.; Cheng, A.; Garrick, T.; Kapoor, V. Preliminary evidence for a link between schizophrenia and NMDA-glycine site receptor ligand metabolic enzymes, D-amino acid oxidase (DAAO) and kyurenine aminotransferase-1 (KAT-1). Brain. Res. 2006, 1106, 205-210.
51. Weidenhofer, J.; Bowden, N.A.; Scott, R.J.; Tooney, P.A. Altered gene expression in the amygdala in schizophrenia: up-regulation of genes located in the cytomatrix active zone. Mol. Cell. Neurosci. 2006, 31, 243-250.
52. Weidenhofer, J.; Yip, J.; Zavitsanou, K.; Huang, X.-F.; Chahl, L.A.; Tooney, P.A. Immunohistochemical localisation of the NK1 receptor in the human amygdala: preliminary investigation in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2006, 30, 1313-1321.
53. Fan, L.; Bellinger, F.; Ge, Y.-L.; Wilce, P. Genetic study of alcoholism and novel gene expression in the alcoholic brain. Addict Biol. 2004, 9, 11-18.
54. Liu, J.; Lewohl, J.M.; Dodd, P.R.; Randall, P.K.; Harris, R.A.; Mayfield, R.D. Gene expression profiling of individual cases reveals consistent transcriptional changes in alcoholic human brain. J. Neurochem. 2004, 90, 1050-1058.
55. Lewohl, J.M.; Wang, L.; Miles, M.F.; Zhang, L.; Dodd, P.R.; Harris, R.A. Gene expression in human alcoholism: microarray analysis of frontal cortex. Alcohol. Clin. Exp. Res. 2000, 24, 1873-1882.
56. Lewohl, J.M.; Dodd, P.R.; Mayfield, R.D.; Harris, R.A. Application of DNA microarrays to study human alcoholism. J. Biomed. Sci. 2001, 8, 28-36.
57. Mayfield, R.D.; Lewohl, J.M.; Dodd, P.R.; Herlihy, A.; Liu, J.; Harris, R.A. Patterns of gene expression are altered in the frontal and motor cortices of human alcoholics. J. Neurochem. 2002, 81, 802-813.
58. Liu, J.; Lewohl, J.; Harris, R.A.; Iyer, V.; Dodd, P.; Randall, P.K.; Mayfield, R.D. Patterns of gene expression in the frontal cortex discriminate alcoholic from nonalcoholic individuals. Neuropsychopharmacology 2006, 31, 1574-1582.
59. Johansson, S.; Ekstrom, T.; Marinova, Z.; Okvist, A.; Sheedy, D.; Garrick, T.; Harper, C.; Kuzmin, A.; Yakovleva, T.; Bakalkin, G. Dysregulation of cell death machinery in the prefrontal cortex of human alcoholics. Int. J. Neuropsychopharmacol. 2008, 12, 1-7.
60. Harper, C.; Dixon, G.; Sheedy, D.; Garrick, T. Neuropathological alterations in alcoholic brains. Studies arising from the New South Wales Tissue Resource Centre. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2003, 27, 951-961.
61. Kril, J.J.; Halliday, G.M.; Svoboda, M.D.; Cartwright, H. The cerebral cortex is damaged in chronic alcoholics. Neuroscience1997, 79, 983-998.
62. Flatscher-Bader, T.; van der Brug, M.; Hwang, J.W.; Gochee, P.A.; Matsumoto, I.; Niwa, S.; Wilce, P.A. Alcohol-responsive genes in the frontal cortex and nucleus accumbens of human alcoholics. J. Neurochem. 2005, 93, 359-370.
63. Flatscher-Bader, T.; van der Brug, M.P.; Landis, N.; Hwang, J.W.; Harrison, E.; Wilce, P.A. Comparative gene expression in brain regions of human alcoholics. Genes. Brain. Behav. 2006, 5, 78-84.
64. Johansson, S.; Fuchs, A.; Okvist, A.; Karimi, M.; Harper, C.; Garrick, T.; Sheedy, D.; Hurd, Y.; Bakalkin, G.; Ekstrom, T. Validation of endogenous controls for quantitative gene expression analysis: application on brain cortices of human chronic alcoholics. Brain. Res. 2007, 1132, 20-28.
65. Mayfield, R.D.; Liu, J.; Randall, P.K.; Lewohl, J.M.; Dodd, P.R.; Harris, R.A. Methods for the identification of differentially expressed genes in human post-mortem brain. Methods 2003, 31, 301-305.
66. Liu, J.; Lewohl, J.M.; Harris, R.A.; Dodd, P.R.; Mayfield, R.D. Altered gene expression profiles in the frontal cortex of cirrhotic alcoholics. Alcohol. Clin. Exp. Res. 2007, 31, 1460-1466.
67. Okvist, A.; Johansson, S.; Kuzmin, A.; Bazov, I.; Merino- Martinez, R.; Ponomarev, I.; Mayfield, R. D.; Harris, R. A.; Sheedy, D.; Garrick, T.; Harper, C.; Hurd, Y.; Terenius, L.; Ekstrom, T.; Bakalkin, G.; Yakovleva, T. Neuroadaptions in Human Chronic Alcoholics: Dysregulation of the NF-KB System. PLoS ONE 2007, 2, e930.
68. Henriksson, R.; Kuzmin, A.; Okvist, A.; Harper, C.; Sheedy, D.; Garrick, T.; Yakovleva, T.; Bakalkin, G. Elevated Synaptophysin I in the Prefrontal Cortex of Human Chronic Alcoholics. Synapse 2008, 62, 829-833.
69. Lewohl, J.M.; Van Dyk, D.D.; Craft, G.E.; Innes, D.J.; Mayfield, R.D.; Cobon, G.; Harris, R. A.; Dodd, P.R. The application of proteomics to the human alcoholic brain. Ann. N. Y. Acad. Sci. 2004, 1025, 14-26.
70. Alexander- Kaufman, K.; Cordwell, S.; Harper, C.; Matsumoto, I. A proteome analysis of the dorsolateral prefrontal cortex in human alcoholic patients. Proteomics. Clin. Appl. 2007, 1, 62-72.
71. Alexander-Kaufman, K.; James, G.; Sheedy, D.; Harper, C.; Matsumoto, I. Differential protein expression in the prefrontal white matter of human alcoholics: a proteomics study. Mol. Psychiatry 2006, 11, 56-65.
72. Alexander- Kaufman, K.; Harper, C. Transketolase: Observations in alcohol-related brain damage research. Biochem. Cell. Biol. 2008, doi:10.1016/j.biocel.2008.04.005.
73. Depaz, I.; Ito, M.; Matsumoto, I.; Niwa, S.; Kroon, P.; Wilce, P.A. Expression of hNP22 is altered in the frontal cortex and hippocampus of the alcoholic human brain. Alcohol. Clin. Exp. Res. 2003, 27, 1481-1488.
74. Kashem, M.; James, G.; Harper, C.; Wilce, P.; Matsumoto, I. Differential protein expression in the corpus callosum (splenium) of human alcoholics: A proteomics study. Neurochem. Int. 2007, 50, 450-459.
75. Kashem, M.A., Harper, C., Matsumoto, I. Differential protein expression in the corpus callosum (Genu) of human alcoholics. Neurochem. Int. 2008, 53, 1-11.
76. Matsuda- Matsumoto, H.; Iwazaki, T.; Kashem, M.A.; Harper, C.; Matsumoto, I. Differential protein expression profiles in the hippocampus of human alcoholics. Neurochem. Int. 2007, 50, 450- 459.
77. Pamphlett, R.; Kum-Jew, S.; King, N.J.C. Flaviviruses in motor neuron disease. Muscle. Nerve. 2005, 32, 108-109.
78. Morahan, J.; Yu, B.; Trent, R.; Pamphlett, R. Are metallothionein genes silenced in ALS? Toxicol. Lett. 2006, 168, 83- 87.
79. Oates, N.; Pamphlett, P. An epigenetic analysis of SOD1 and VEGF in ALS. Amyotroph. Lateral. Scler. 2007, 8, 83-86.
80. Pamphlett, R.; Kum Jew, S. TDP-43 inclusions do not protect motor neurons from sporadic ALS. Acta. Neuropathol. 2008, 116, 221-222.
81. Saunderson, R.; Yu, B.; Trent, R.; Pamphlett, R. A comparison of the lengths of androgen receptor triplet repeats in brain and blood in motor neuron diseases. J. Neurol. Sci. 2008, 267, 125-128.
82. Ruff, M.; Pamphlett, R. A simple method for comparing microarray genotype data between brain and other tissues. J. Neurosci. Methods. 2008, 173, 315-317.
83. Fedorow, H.; Halliday, G.M.; Rickert, C.H.; Gerlach, M.; Riederer, P.; Double, K.L. Evidence for specific phases in the development of human neuromelanin. Neurobiol. Aging. 2006, 27, 506-512.
84. Halliday, G.; Fedorow, H.; Rickert, C.H.; Gerlach, M.; Reiderer, P.; Double, K.L. Evidence for specific phases in the development of human neuromelanin. Neutral. Transm. 2006, 113, 721-728.
85. Cullen, K. M. Perivascular astrocytes within Alzheimer's disease plaques. Neuroreport 1997, 8, 1961-1966.
86. Cullen, K.M.; Halliday, G.M. Neurofibrillary degeneration and cell loss in the nucleus basalis n comparison to cortical Alzheimer pathology. Neurobiol. Aging. 1998, 19, 297-306.
87. Laws, S. M.; Hone, E.; Taddei, K.; Harper, C.; Dean, B.; McClean, C.; Masters, C.; Lautenschlager, N.; Gandy, S.E.; Martins, R.N. Variation at the APOE -491 promoter locus is associated with altered brain levels of apolipoprotein E. Mol. Psychiatry. 2002, 7, 886-890.
88. Kwok, J.; Loy, C.; Hamilton, G.; Lau, E.; Hallupp, M.; Williams, J.; Owen, M.; Broe, A.; Tang, N.; Lam, L.; Powell, J.; Lovestone, S.; Schofield, P. Glycogen synthase kinase-3p and Tau Genes Interact in Alzheimer's disease. Ann. Neurol. 2008, 64, 446-454.
89. Sokolova, A.; Hill, M.; Rahimi, F.; Warden, L.; Halliday, G.; Shepherd, C. Monocyte Chemoattractant Protein-1 plays a dominant role in the chronic inflammation observed in Alzheimer's disease. Brain. Pathol. 2008, 1-7.
90. Sutherland, G.T.; Nowak, G.; Halliday, G.M.; Kril, J. Tau isoform expression in frontotemporal dementia without tau deposition. J. Clin. Neurosci. 2007, 14, 1182-1185.